Literature DB >> 12376370

Receptors and signaling pathway underlying relaxations to isoprostanes in canine and porcine airway smooth muscle.

Adriana Catalli1, Dawei Zhang, Luke J Janssen.   

Abstract

Using muscle bath techniques, we examined the inhibitory activities of several E- and F-ring isoprostanes in canine and porcine airway smooth muscle. 8-Isoprostaglandin E1 and 8-isoprostaglandin E2 (8-iso PGE2) reversed cholinergic tone in a concentration-dependent manner, whereas the F-ring isoprostanes were ineffective. Desensitization with 8-iso-PGE2 and PGE2 implicated isoprostane activity at the PGE2 receptor (EP). We found that the inhibitory E-ring isoprostane responses were significantly augmented by rolipram (a type IV phosphodiesterase inhibitor), while 1H-[1,2,4]-oxadiazolo[4,3-a]quinoxalin-1-one (a guanylate cyclase inhibitor) had no effect, suggesting a role for cAMP in isoprostane-mediated relaxations. 8-Iso-PGE2 did not reverse KCl tone, suggesting that voltage-dependent Ca2+ influx and myosin light chain kinase are not suppressed by isoprostanes. Patch-clamp studies showed marked suppression of K+ currents by 8-iso-PGE2. We conclude that E-ring isoprostanes exert PGE2 receptor-directed, cAMP-dependent relaxations in canine and porcine airway smooth muscle. This activity is not dependent on K+ channel activation or the direct inhibition of voltage-operated Ca2+ influx or myosin light chain kinase.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12376370     DOI: 10.1152/ajplung.00038.2002

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  5 in total

1.  Vasoconstrictor responses, and underlying mechanisms, to isoprostanes in human and porcine bronchial arterial smooth muscle.

Authors:  Tracy Tazzeo; John Miller; Luke J Janssen
Journal:  Br J Pharmacol       Date:  2003-09-22       Impact factor: 8.739

Review 2.  Isoprostanes and asthma.

Authors:  Judith A Voynow; Apparao Kummarapurugu
Journal:  Biochim Biophys Acta       Date:  2011-05-08

3.  In vitro and in vivo characterization of PF-04418948, a novel, potent and selective prostaglandin EP₂ receptor antagonist.

Authors:  K J af Forselles; J Root; T Clarke; D Davey; K Aughton; K Dack; N Pullen
Journal:  Br J Pharmacol       Date:  2011-12       Impact factor: 8.739

Review 4.  Role of oxidized lipids in pulmonary arterial hypertension.

Authors:  Salil Sharma; Grégoire Ruffenach; Soban Umar; Negar Motayagheni; Srinivasa T Reddy; Mansoureh Eghbali
Journal:  Pulm Circ       Date:  2016-09       Impact factor: 3.017

5.  Isolated porcine bronchi provide a reliable model for development of bronchodilator anti-muscarinic agents for human use.

Authors:  G D'Agostino; A M Condino; L Gioglio; F Zonta; M Tonini; A Barbieri
Journal:  Br J Pharmacol       Date:  2008-06-02       Impact factor: 8.739

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.